Want to see JP:4461 full AI Analyst Report?
4461 Stock Chart & Stats
¥8230.00
-¥60.00(-1.64%)
At close: 4:00 PM EST
¥8230.00
-¥60.00(-1.64%)
Day’s Range― - ―
52-Week Range¥3,785.00 - ¥13,540.00
Previous CloseN/A
Volume29.40K
Average Volume (3M)144.71K
Market Cap
¥136.50B
Enterprise Value¥140.09B
Total Cash (Recent Filing)¥15.44B
Total Debt (Recent Filing)¥29.98B
Price to Earnings (P/E)21.4
Beta1.59
Next Earnings
Jul 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.24%
Share Statistics
EPS (TTM)309.33
Shares Outstanding10,684,321
10 Day Avg. Volume174,660
30 Day Avg. Volume144,713
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.45
Price to Sales (P/S)0.91
P/FCF Ratio11.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)612.6
Revenue Forecast (FY)¥87.00B
Bulls Say, Bears Say
Bulls Say
Revenue And Margin Recovery In 2026The 2026 rebound—double-digit revenue growth and materially higher net margin—signals durable improvement in pricing, mix and operating leverage. Sustained higher margins increase free cash flow capacity, enabling reinvestment, R&D and debt reduction over the next several quarters.
Improved Leverage And Balance-sheet RepairA marked decline in debt-to-equity reflects successful deleveraging and equity accretion, enhancing financial flexibility. Lower leverage reduces interest burden and refinancing risk, making capital allocation (capex, dividends, M&A) more manageable across business cycles in the medium term.
Stronger Free Cash Flow And Earnings QualityConsistent positive free cash flow at a high share of net income indicates improving cash conversion and earnings quality. Reliable FCF supports sustainable funding of working capital, targeted capex and R&D for specialty chemicals, and creates room for continued deleveraging or shareholder returns over coming quarters.
Bears Say
Earnings And Cash-flow CyclicalityHistorical swings from a loss in 2023 to a rebound in 2026 show the business is cyclical and sensitive to end-market demand and pricing. Such volatility undermines forecast visibility, complicates capital allocation and increases the chance of margin pressure or cash stress during downcycles.
Material Absolute Debt Remains (~¥29B)A sizable absolute debt load keeps fixed financing costs elevated and leaves the company exposed if profitability weakens. Even with improved ratios, the absolute debt level could constrain investment flexibility and heighten refinancing or covenant risk in adverse macro or industry conditions.
Working-capital Sensitivity And Uneven OCF CoverageModest operating cash flow relative to revenue and past negative OCF demonstrate vulnerability to working-capital swings and capex cycles. This structural sensitivity can magnify earnings volatility, force short-term financing needs and constrain the pace of sustainable investment or shareholder returns.
DKS Co., Ltd. News
4461 FAQ
What was DKS Co., Ltd.’s price range in the past 12 months?
DKS Co., Ltd. lowest stock price was ¥3785.00 and its highest was ¥13540.00 in the past 12 months.
What is DKS Co., Ltd.’s market cap?
DKS Co., Ltd.’s market cap is ¥136.50B.
When is DKS Co., Ltd.’s upcoming earnings report date?
DKS Co., Ltd.’s upcoming earnings report date is Jul 23, 2026 which is in 21 days.
How were DKS Co., Ltd.’s earnings last quarter?
DKS Co., Ltd. released its earnings results on May 13, 2026. The company reported ¥184.29 earnings per share for the quarter, beating the consensus estimate of N/A by ¥184.29.
Is DKS Co., Ltd. overvalued?
According to Wall Street analysts DKS Co., Ltd.’s price is currently Overvalued.
Does DKS Co., Ltd. pay dividends?
DKS Co., Ltd. pays a Semiannually dividend of ¥74 which represents an annual dividend yield of 1.24%. See more information on DKS Co., Ltd. dividends here
What is DKS Co., Ltd.’s EPS estimate?
DKS Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does DKS Co., Ltd. have?
DKS Co., Ltd. has 10,684,321 shares outstanding.
What happened to DKS Co., Ltd.’s price movement after its last earnings report?
DKS Co., Ltd. reported an EPS of ¥184.29 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.714%.
Which hedge fund is a major shareholder of DKS Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4461
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DKS Co., Ltd.
Headquartered in Kyoto, Japan, DKS Co. Ltd. is a global producer and purveyor of a diverse range of industrial chemicals and surfactants, serving numerous industries worldwide. The company’s operations are organized into six distinct segments: Surfactants, Amenity Materials, Polyurethane Materials, Functional Materials, Electronic Device Materials, and Life Sciences. Within its Surfactants division, DKS develops various types such as nonionic, anionic, cationic, polymerizable, and amphoteric compounds, in addition to specialized surfactant blends. The Amenity Materials segment features products like sucrose fatty acid esters, sodium carboxymethyl celluloses, cellulose nanofibers and other polymers, polyvinyl pyrrolidone, polyacrylamide and polyacrylate, and industrial deodorizers. Its Polyurethane Materials offerings include polyether polyols, urethane prepolymers, and comprehensive urethane systems. For Functional Materials, DKS manufactures radiation-curable monomers and oligomers, waterborne polyurethanes, flame retardants, and amide-based lubricants. The Electronic Device Materials group supplies ionic liquids, ion-conductive polymers, ceramic/metal injection molding components, conductive pastes for electronic applications, injection molding pellets, and advanced inorganic materials. Furthermore, the Life Sciences segment crafts health and dietary supplements, notably an I. Japonica-Bombyx Fungus product and Sudachin, a distinct citrus peel extract powder. Founded in 1909, the firm was formerly known as Dai-ichi Kogyo Seiyaku Co., Ltd. before rebranding to DKS Co. Ltd. in 2013.
Technical Analysis
T Hasegawa Co
―
Sanyo Chemical Industries
―
Tri Chemical Laboratories Inc.
―
Takasago International Corporation
―
MEC Company Ltd.
―
Options Prices
Currently, No data available
---